Immunotherapy Drug Boosts Survival for Lung Cancer Patients

THURSDAY, Oct. 1, 2020 — A newly approved drug for the leading form of the number one cancer killer, lung cancer, does improve patient survival, a new study confirms.
The immunotherapy drug Tecentriq (atezolizumab) was approved earlier this year by…
Source: Topamax